$BMY posts its earnings report demonstrating solid execution amidst ongoing challenges. Key highlights include a revenue growth of 9% in Q4 and a focus on operational excellence, with an expected 2025 revenue of ~$45.5 billion. Risks include significant LOEs impacting the legacy portfolio, particularly for Revlimid. Noteworthy projections for non-GAAP EPS are between $6.55 to $6.85. Future growth may hinge on new therapies like Cobinfi and strengthened market positions. 🧬📈 Check details at valueverge.com/BMY.

$COP has released its fourth-quarter 2024 earnings, showcasing solid operational execution. The company reported adjusted earnings of $1.98 per share and generated over $5.4 billion in cash flow. Notable highlights include a 4% year-over-year production growth, bolstered by the recent Marathon acquisition, and a strong capital return strategy targeting $10 billion in shareholder distributions.

$HON just released its Q4 2024 earnings report, highlighting strong performance despite ongoing macroeconomic challenges. The company met or exceeded guidance for organic and adjusted earnings growth. Key stats: Organic sales up 3% for the full year, with a notable backlog of $35.3B and segment margins under pressure due to recent acquisitions and product mix. Looking forward, Honeywell is navigating geopolitical uncertainties and planning a strategic separation of its Automation and Aerospace sectors by 2026. 🚀⚠️ For detailed insights: valueverge.com/HON.

$PM has released its earnings report, showcasing a strong performance in Q4 2024 and overall growth for the year. Key highlights include an organic net revenue growth of +9.8% and a robust +14.9% increase in organic operating income. However, there are currency and supply chain headwinds to address. 📈

$AZN has released its latest earnings report, showcasing robust growth and developments. Total revenue surged 21% year-over-year, with a core EPS increase of 19%. While the company reported potential risks in China, ongoing investigations could impact their operations. Highlights include steady growth across various therapy areas and expectations of continued innovation. ⚕️💰 Investors should note the evolving market conditions while anticipating future opportunities. For detailed insights, visit valueverge.com/AZN.

$LIN reports solid Q4 results with a flat sales of $8.3B and a margin of 29.9%. ⚖️ Key metrics show 25.9% return on capital and a 10% EPS growth, despite FX headwinds. Valuation aligns with strong historical performance, but future FX risks loom.

$LLY has just released its Q4 2024 earnings report, highlighting robust revenue growth of 45% compared to Q4 2023, driven by strong performance from Mounjaro and Zepbound. Key risks include the competitive landscape in the incretin market and ongoing pricing pressures.

$AMZN has released its Q4 2024 earnings, showing 10% year-over-year revenue growth to $187.8 billion despite a significant foreign exchange headwind. Operating income surged 61% to $21.2 billion, reflecting improved profitability. Key insights reveal strong growth in AWS by 19% YOY and advertising revenue up 18%.

Trending stocks, Feb 6 2025

$JCI has released its Q4 fiscal 2024 earnings, showing strong performance with a 10% organic revenue growth and significant margin expansion. Key stats include an adjusted EPS growth of 22% YoY and a robust 96% adjusted free cash flow conversion. Despite risks from restructuring and capital deployment, the future looks promising with a record backlog of $13.1 billion, driven by data center demand. For fiscal 2025, guidance suggests adjusted EPS between $3.40 and $3.50, with expected growth of 6%-9%. Explore more details at valueverge.com/JCI. 📈💼